Pfizer Financials

PFE Stock  USD 25.48  0.19  0.75%   
Based on the analysis of Pfizer's profitability, liquidity, and operating efficiency, Pfizer Inc may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At present, Pfizer's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 34.5 B, whereas Cash And Short Term Investments are forecasted to decline to about 15.1 B.
Historical analysis of Pfizer income statement accounts such as Other Operating Expenses of 28.5 B, Operating Income of 11.1 B, EBIT of 9.8 B or Ebitda of 13.6 B can show how well Pfizer Inc performed in making a profits. Evaluating Pfizer income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Pfizer's future profits or losses.
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Pfizer Income Statement Chart

At present, Pfizer's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Cost Of Revenue is expected to grow to about 26.3 B, whereas Gross Profit is forecasted to decline to about 28.5 B.
Key indicators impacting Pfizer's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Net Profit Margin0.140.11
Significantly Up
Very volatile
Return On Assets0.04110.0432
Notably Down
Pretty Stable
Return On Equity0.09930.1
Slightly Down
Very volatile
Debt Equity Ratio0.360.68
Way Down
Slightly volatile
Operating Income11.1 B19 B
Way Down
Pretty Stable
Current Ratio1.731.35
Significantly Up
Slightly volatile
The essential information of the day-to-day investment outlook for Pfizer includes many different criteria found on its balance sheet. An individual investor should monitor Pfizer's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Pfizer.

Cash And Equivalents

1.27 Billion

  
Build AI portfolio with Pfizer Stock

Pfizer Inc Earnings Geography

Please note, the presentation of Pfizer's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pfizer's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Pfizer's management manipulating its earnings.

Pfizer Stock Summary

Pfizer competes with Gilead Sciences, Sanofi ADR, Amgen, GlaxoSmithKline PLC, and Bristol Myers. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 79000 people.
Foreign Associates
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNew York Stock Exchange
ISINUS7170811035
Business Address66 Hudson Boulevard
SectorPharmaceuticals
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.pfizer.com
Phone212 733 2323
CurrencyUSD - US Dollar

Pfizer Key Financial Ratios

Pfizer Key Balance Sheet Accounts

202120222023202420252026 (projected)
Total Assets181.5B197.2B226.5B213.4B245.4B257.7B
Other Current Liab31.8B29.9B27.5B28.5B32.8B34.5B
Net Debt35.1B34.5B72.2B66.0B75.8B79.6B
Retained Earnings103.4B125.7B118.4B116.7B134.2B140.9B
Cash1.9B416M2.9B1.0B1.2B2.0B
Net Receivables15.7B14.5B11.2B14.8B17.0B8.5B
Inventory9.1B9.0B10.2B10.9B12.5B13.1B
Other Current Assets3.8B5.0B9.3B4.3B4.9B3.9B
Total Liab104.0B101.3B137.2B124.9B143.6B150.8B
Total Current Assets59.7B51.3B43.3B50.4B57.9B32.8B
Short Term Debt2.2B2.9B10.9B7.3B8.4B5.8B
Intangible Assets25.1B43.4B64.9B55.4B63.7B66.9B
Accounts Payable5.6B6.8B6.7B5.6B6.5B6.8B
Capital Stock473M476M478M480M552M476.1M
Common Stock473M476M478M480M552M476.1M
Other Liab29.7B26.6B22.6B23.3B26.9B22.1B
Other Assets5.6B6.8B6.7B16.2B18.6B19.6B
Long Term Debt36.2B32.9B60.5B56.7B65.2B68.5B
Good Will49.2B51.4B67.8B68.5B78.8B42.1B
Treasury Stock(111.0B)(111.4B)(114.0B)(114.5B)(103.0B)(97.9B)
Net Tangible Assets63.2B77.2B95.7B89.0B102.4B107.5B

Pfizer Key Income Statement Accounts

202120222023202420252026 (projected)
Interest Expense1.3B1.2B2.2B3.1B3.6B3.7B
Total Revenue81.3B100.3B59.6B63.6B73.2B39.6B
Gross Profit46.9B62.1B30.3B41.8B48.1B28.5B
Operating Income20.8B37.5B5.3B16.5B19.0B11.1B
Ebit25.6B36.0B3.3B11.1B12.8B9.8B
Ebitda30.8B41.0B9.6B18.1B20.8B13.6B
Cost Of Revenue34.4B38.2B29.2B21.8B25.0B26.3B
Income Before Tax24.3B34.7B1.1B8.0B9.2B8.6B
Net Income22.1B31.4B2.1B8.0B9.2B7.8B
Income Tax Expense1.9B3.3B(1.1B)(28M)(32.2M)(30.6M)
Research Development13.8B11.4B10.6B10.7B12.3B8.2B
Minority Interest(45M)(35M)(39M)(31M)(27.9M)(26.5M)
Non Recurring747M600M802M2.3B2.1B1.3B
Tax Provision1.9B3.3B(1.1B)(28M)(32.2M)(30.6M)
Interest Income560M1.8B1.6B545M626.8M891.9M
Extraordinary Items(434M)6M(15M)11M9.9M9.4M
Net Interest Income(1.3B)(987M)(585M)(2.5B)(2.3B)(2.2B)

Pfizer Key Cash Accounts

202120222023202420252026 (projected)
Change To Inventory(1.1B)592M6.2B(854M)(982.1M)(933.0M)
Change In Cash158M(1.5B)2.4B(1.8B)(1.6B)(1.5B)
Free Cash Flow29.9B26.0B4.8B9.8B11.3B10.6B
Depreciation5.2B5.1B6.3B7.0B8.1B4.2B
Other Non Cash Items(4.8B)150M5.3B2.0B1.8B1.9B
Dividends Paid8.7B9.0B(9.2B)(9.5B)(10.9B)(10.4B)
Capital Expenditures2.7B3.2B3.9B2.9B3.3B1.9B
Net Income22.5B31.4B2.2B8.1B9.3B9.3B
End Period Cash Flow2.0B468M2.9B1.1B1.3B2.1B
Change To Netincome2.9B2.9B(7.3B)(2.7B)(2.5B)(2.3B)
Investments(19.5B)11.1B(32.3B)2.7B3.0B3.2B
Change Receivables(742M)(1.2B)(3.8B)261M234.9M246.6M
Net Borrowings(1.1B)(3.5B)35.9B(7.2B)(6.4B)(6.1B)

Pfizer Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Pfizer's current stock value. Our valuation model uses many indicators to compare Pfizer value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pfizer competition to find correlations between indicators driving Pfizer's intrinsic value. More Info.
Pfizer Inc is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers reporting about  0.49  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Pfizer Inc is roughly  2.04 . At present, Pfizer's Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Pfizer by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Most accounts from Pfizer's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Pfizer Inc current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.
At present, Pfizer's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Cost Of Revenue is expected to grow to about 26.3 B, whereas Gross Profit is forecasted to decline to about 28.5 B.
 2023 2024 2025 2026 (projected)
Gross Profit30.3B41.8B48.1B28.5B
Total Revenue59.6B63.6B73.2B39.6B

Pfizer income statement Correlations

0.720.450.560.470.330.150.330.380.720.09-0.580.070.030.890.43-0.050.14-0.07-0.270.1-0.02-0.15-0.13-0.01-0.34
0.720.280.290.360.09-0.060.040.460.47-0.13-0.59-0.13-0.10.420.51-0.5-0.11-0.16-0.090.060.11-0.16-0.25-0.14-0.8
0.450.280.960.960.870.80.870.850.820.75-0.150.670.170.420.84-0.46-0.080.52-0.180.090.210.080.02-0.09-0.16
0.560.290.960.880.920.810.90.720.840.76-0.240.670.220.550.74-0.260.030.49-0.260.060.080.090.01-0.05-0.16
0.470.360.960.880.70.650.740.870.880.59-0.130.550.080.410.91-0.54-0.150.38-0.210.140.290.0-0.06-0.09-0.19
0.330.090.870.920.70.910.940.650.560.89-0.160.760.30.360.53-0.240.070.67-0.08-0.020.030.210.17-0.08-0.08
0.15-0.060.80.810.650.910.970.650.451.00.230.910.290.190.54-0.230.060.85-0.25-0.240.340.220.08-0.05-0.02
0.330.040.870.90.740.940.970.660.610.950.120.880.280.370.6-0.190.10.77-0.28-0.160.30.180.05-0.04-0.04
0.380.460.850.720.870.650.650.660.610.61-0.120.550.060.240.84-0.77-0.250.51-0.07-0.010.360.030.01-0.17-0.31
0.720.470.820.840.880.560.450.610.610.38-0.280.370.050.660.82-0.23-0.040.12-0.430.150.13-0.1-0.20.0-0.23
0.09-0.130.750.760.590.891.00.950.610.380.280.910.30.150.47-0.190.070.87-0.24-0.270.320.240.1-0.040.04
-0.58-0.59-0.15-0.24-0.13-0.160.230.12-0.12-0.280.280.380.0-0.47-0.050.140.010.42-0.3-0.440.630.07-0.140.110.33
0.07-0.130.670.670.550.760.910.880.550.370.910.38-0.070.10.47-0.15-0.050.95-0.36-0.30.41-0.1-0.150.3-0.02
0.03-0.10.170.220.080.30.290.280.060.050.30.0-0.070.170.030.020.35-0.10.16-0.140.040.960.49-0.850.15
0.890.420.420.550.410.360.190.370.240.660.15-0.470.10.170.30.130.1-0.05-0.150.05-0.04-0.010.01-0.04-0.07
0.430.510.840.740.910.530.540.60.840.820.47-0.050.470.030.3-0.65-0.280.32-0.33-0.120.45-0.01-0.28-0.11-0.45
-0.05-0.5-0.46-0.26-0.54-0.24-0.23-0.19-0.77-0.23-0.190.14-0.150.020.13-0.650.51-0.22-0.26-0.01-0.41-0.10.010.340.52
0.14-0.11-0.080.03-0.150.070.060.1-0.25-0.040.070.01-0.050.350.1-0.280.51-0.13-0.09-0.01-0.130.180.32-0.070.24
-0.07-0.160.520.490.380.670.850.770.510.120.870.420.95-0.1-0.050.32-0.22-0.13-0.19-0.340.43-0.09-0.090.27-0.04
-0.27-0.09-0.18-0.26-0.21-0.08-0.25-0.28-0.07-0.43-0.24-0.3-0.360.16-0.15-0.33-0.26-0.09-0.190.3-0.180.270.43-0.350.03
0.10.060.090.060.14-0.02-0.24-0.16-0.010.15-0.27-0.44-0.3-0.140.05-0.12-0.01-0.01-0.340.3-0.52-0.210.360.010.24
-0.020.110.210.080.290.030.340.30.360.130.320.630.410.04-0.040.45-0.41-0.130.43-0.18-0.520.1-0.28-0.14-0.29
-0.15-0.160.080.090.00.210.220.180.03-0.10.240.07-0.10.96-0.01-0.01-0.10.18-0.090.27-0.210.10.43-0.90.1
-0.13-0.250.020.01-0.060.170.080.050.01-0.20.1-0.14-0.150.490.01-0.280.010.32-0.090.430.36-0.280.43-0.360.51
-0.01-0.14-0.09-0.05-0.09-0.08-0.05-0.04-0.170.0-0.040.110.3-0.85-0.04-0.110.34-0.070.27-0.350.01-0.14-0.9-0.360.09
-0.34-0.8-0.16-0.16-0.19-0.08-0.02-0.04-0.31-0.230.040.33-0.020.15-0.07-0.450.520.24-0.040.030.24-0.290.10.510.09
Click cells to compare fundamentals

Pfizer Account Relationship Matchups

Pfizer income statement Accounts

202120222023202420252026 (projected)
Interest Expense1.3B1.2B2.2B3.1B3.6B3.7B
Total Revenue81.3B100.3B59.6B63.6B73.2B39.6B
Gross Profit46.9B62.1B30.3B41.8B48.1B28.5B
Operating Income20.8B37.5B5.3B16.5B19.0B11.1B
Ebit25.6B36.0B3.3B11.1B12.8B9.8B
Ebitda30.8B41.0B9.6B18.1B20.8B13.6B
Cost Of Revenue34.4B38.2B29.2B21.8B25.0B26.3B
Income Before Tax24.3B34.7B1.1B8.0B9.2B8.6B
Net Income22.1B31.4B2.1B8.0B9.2B7.8B
Income Tax Expense1.9B3.3B(1.1B)(28M)(32.2M)(30.6M)
Research Development13.8B11.4B10.6B10.7B12.3B8.2B
Minority Interest(45M)(35M)(39M)(31M)(27.9M)(26.5M)
Non Recurring747M600M802M2.3B2.1B1.3B
Tax Provision1.9B3.3B(1.1B)(28M)(32.2M)(30.6M)
Interest Income560M1.8B1.6B545M626.8M891.9M
Extraordinary Items(434M)6M(15M)11M9.9M9.4M
Net Interest Income(1.3B)(987M)(585M)(2.5B)(2.3B)(2.2B)

Pfizer Thematic Clasifications

Pfizer Inc is part of several thematic ideas from Healthcare to Robots And Drones. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Pfizer Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Pfizer's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Pfizer growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0576

At present, Pfizer's Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.

Pfizer January 10, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Pfizer help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Pfizer Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Pfizer Inc based on widely used predictive technical indicators. In general, we focus on analyzing Pfizer Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Pfizer's daily price indicators and compare them against related drivers.

Complementary Tools for Pfizer Stock analysis

When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Transaction History
View history of all your transactions and understand their impact on performance
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Fundamental Analysis
View fundamental data based on most recent published financial statements